
Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.